Please assess the completion status of the following clinical trial:

Trial Title: Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic hepatitis B, hepatitis B e-antigen negative, hepatitis B e-antibody positive, and hepatitis B surface antigen-positive~* Hepatitis B e Antigen (HBeAg)-negative at the beginning of TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine)~* Received continuous TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine) treatment for at least 4 years prior to screening. If TDF has been used in combination with lamivudine or emtricitabine, lamivudine or emtricitabine must have been stopped at least 12 weeks prior to screening~* Documented hepatitis B virus DNA (HBV DNA) \< 400 copies/mL for at least 3.5 years prior to screening and at screening~* ALT within normal range~* α-fetoprotein (AFP) \<= 50 ng/mL~* Calculated creatinine clearance \>= 70 mL/min by Cockcroft-Gault formula using ideal body weight~* \<= 10 kPa on Fibroscan assessment~* A negative serum pregnancy test for female subjects~* Adult subjects \>= 18 years of age~Key Exclusion Criteria:~* Known cirrhosis~* Evidence of fibrosis \>= Stage 3 (METAVIR) on liver biopsy or Fibroscan \> 10 kPa within 6 months prior to screening~* Documentation of confirmed episodes (i.e., 2 consecutive values) of HBV DNA \> 400 copies/mL within 3.5 years prior to screening~* History of decompensated liver disease (defined as direct \[conjugated\] bilirubin \> 1.5 x upper limit of normal, prothrombin time (PT) \> 1.5 x upper limit of normal, platelets \< 75,000/mm³, serum albumin \< 3.0 g/dL~* History of clinical hepatic decompensation in the judgement of the investigator~* Evidence of hepatocellular carcinoma~* Significant bone disease (in the judgment of the investigator)~* Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D infection~* Known hypersensitivity to TDF, its metabolites, or formulation excipients~* Concomitant therapy with disallowed medications~* History of malignant disease~* Lactating females~* Females wishing to became pregnant during the duration of the stud~* Subjects participating in another clinical trial can only be enrolled at the discretion of the Medical Monitor~Note: Other protocol defined inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stop TDF (Type: EXPERIMENTAL): Participants randomized to this arm will stop TDF therapy at baseline.
- Continue TDF (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will continue TDF therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).